PrognomIQ
San Mateo, US · Founded 2020 · Delaware corporation · 40 employees on LinkedIn · 4 known investors
Founders & leadership
PrognomIQ was founded in 2020 by Philip Ma, Ph.D..
PM
Philip Ma, Ph.D.Founder
BK
Brian Koh, M.D.Executive
DS
David SiewersExecutive
OF
Omid Farokhzad, M.D.Named on SEC filing
Board
Investors · 4
Reported raises · per SEC filings
Form D private placements$56.2M disclosed across 3 rounds · 2024–2026
▶$11.9MraisedJan 2026 · 6 investors · Other Health CareRule 506(b)
▶$11.9MraisedJan 2026 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rajesh Garg, M.D.Director
- Brian Koh, M.D.Executive Officer
- Omid C. Farokhzad, M.D.Director
- Bruce Wilcox, Ph.D.Executive Officer
- Isaac Ro, Ph.D.Director
- David L. SiewersExecutive Officer
- Mark B. McClellan, M.D., Ph.D.Director
- Philip Ma, Ph.D.Executive Officer, Director
- Tomer Berkovitz, Ph.D.Director
- Offering amount
- $11.9M
- Amount sold
- $11.9M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedAug 2025 · 9 investors · Other Health CareRule 506(b)
▶$10MraisedAug 2025 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rajesh Garg, M.D.Director
- Mark B. McClellan, M.D., Ph.D.Director
- Philip Ma, Ph.D.Executive Officer, Director
- Bruce Wilcox, Ph.D.Executive Officer
- Joel KaufmanExecutive Officer
- Omid C. Farokhzad, M.D.Director
- Isaac Ro, Ph.D.Director
- Tomer Berkovitz, Ph.D.Director
- Brian Koh, M.D.Executive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$34.3MraisedAug 2024 · 10 investors · Other Health CareRule 506(b)
▶$34.3MraisedAug 2024 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rajesh GargDirector
- Philip Ma, Ph.D.Executive Officer, Director
- Omid Farokhzad, M.D.Director
- Tomer Berkovitz, Ph.D.Director
- Mark McClellan, M.D., Ph.D.Director
- Brian Koh, M.D.Executive Officer
- David SiewersExecutive Officer
- Isaac RoDirector
- Offering amount
- $34.3M
- Amount sold
- $34.3M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Nomic Bio8 shared keywordsNomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.
Phenomic AI8 shared keywordsPhenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Predictive Oncology7 shared keywordsPredictive Oncology combines machine learning with data from a large privately held biobank of over 150,000 tumor samples and 3D in vitro tumor models to predict drug response for pre-clinical drug discovery. It also offers tumor drug-response testing and genomic profiling services to personalize cancer therapies, serving biopharma partners and clinical oncology.
IDbyDNA7 shared keywordsScalable, high throughput DNA sequencing platforms.
Nautilus Biotechnology5 shared keywordsNautilus develops proteomics technology to unlock the complexity of the human proteome for biomedical research and diagnostics. The company targets pharmaceutical, biotechnology, academic, clinical, and government sectors with advanced protein quantification and analysis platforms.
Macrogenics Inc5 shared keywordsMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.
Companies competing with PrognomIQ for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who founded PrognomIQ?
- PrognomIQ was founded by Philip Ma, Ph.D. in 2020.
- Who are PrognomIQ's investors?
- PrognomIQ's investors include aMoon, Catalio Capital Management, LP, Wing, Maverick Ventures.
- How much funding has PrognomIQ raised?
- PrognomIQ has disclosed $56.2M raised across 3 rounds.
- Where is PrognomIQ headquartered?
- PrognomIQ is headquartered in San Mateo, US.